Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors
Oral squamous cell carcinoma and hyperkeratotic lesions with BRAF inhibitors
复制标题
BRAF抑制剂治疗口腔鳞状细胞癌和角化过度病变
DOI：
--
复制
发表时间：
2015
影响因子：
10.3
通讯作者：
V. Sibaud
中科院分区：
文献类型：
--
作者：
E. Vigarios;Laurence Lamant;J. P. Delord;J;C. Chevreau;B. Barres;C. Gomez;M. Boulanger;V. Sibaud
特定生物制品：目前的知识和未来的展望。Tther Drug Monit 2013；35：588-94。3 Carrascoa JM，van Doorn MB，Lahfa M等人。牛皮癣生物制剂免疫原性的临床相关性：治疗策略的意义。J EUR Acad Dermatol Venereol 2014；28：1424-30。4 Jani M，Barton A，Warren RB等人。DMARDS在降低慢性炎症性疾病中肿瘤坏死因子抑制剂免疫原性中的作用。风湿病(牛津)2014；53：213-22。5 Patherana D，Ormerod AD，Saiag P et al.欧洲S3-寻常型银屑病系统治疗指南。J EUR Acad Dematol Venereol 2009；23(补充2)：1比70。6 Gottlieb AB，Langley RG，Strober Be等人。一项随机、双盲、安慰剂对照研究，旨在评估中重度斑块型银屑病患者在依那西普的基础上加用甲氨蝶呤。BR J Dermatol 2012；167：649-57。7 Klareskog L，van der Heijde D，de Jager JP等人。依那西普联合甲氨蝶呤与单独用药治疗类风湿关节炎的疗效比较：双盲随机对照试验。《柳叶刀》2004；363：675-81。8 Keystone EC，van der Heijde D，Kavanaugh A等人。阿达利单抗联合甲氨蝶呤的长期临床、功能和放射学益处：长期类风湿性关节炎的最终10年数据。J Rheumatol 2013；40：1487-97。9 St Clair EW，van derHeijde DM，Smolen JS等人。英夫利昔单抗联合甲氨蝶呤治疗早期类风湿性关节炎：一项随机对照试验。关节炎大黄2004；50：3432-43。10 Smolen JS，Landewe R，Breedveld FC等人。使用合成和生物抗风湿药物治疗类风湿性关节炎的EULAR建议：2013年更新。Ann Rheum Dis 2014；73：492-509。11 Gisondi P，Targher G，Zoppini G等人。慢性斑块型银屑病患者中的非酒精性脂肪性肝病。《肝病杂志》2009年；51：758--。12 van der Voort EA，Koehler EM，Dowlatshahi EA等人。银屑病与55岁或55岁以上患者中的非酒精性脂肪性肝病独立相关：一项基于人群的研究结果。J am Acad Dermatol 2014；70：517-24。13 Lopez-Ferrer A，Vilarrasa E，Gich IJ等人。阿达利单抗在现实生活中治疗牛皮癣：一项在西班牙一个中心对119名患者进行的回顾性队列研究。BR J Dermatol 2013；169：1141-7.14 Antoniou C，Dessinioti C，Vergou T等人。生物制剂序贯治疗：35例高需求银屑病患者从依法利珠单抗改为依那西普。J EUR Acad Dermatol Venereol 2010；24：1413-20.15菲利普·S、威尔斯曼-泰斯·D、魏尔格拉夫·A等人。阿达利单抗联合传统全身性抗银屑病药物治疗银屑病39例J Dtsch dermatol GES 2012；10：821-37。16 van den Reek JM，van L Eulumig PP，Kievit W等人。阿达利单抗剂量递增、阿达利单抗与甲氨蝶呤联合治疗或两者联合治疗银屑病患者的疗效。J dermatolog Treatment 2013；24：361-8.17 Dalaker M，Bones rónning JH。英夫利昔单抗联合甲氨蝶呤或硫唑嘌呤长期维持治疗中重度斑块型银屑病的回顾性队列研究。J EUR Acad Dermatol Venereol 2009；23：277-82。18 Driessen RJ，van de Kerkhof PC，de Jong EM。依那西普联合甲氨蝶呤治疗高需求银屑病。BR J Dermatol 2008；159：460-3.19 Zachariae C，Mórk NJ，Reunala T et al.尽管甲氨蝶呤治疗效果不佳，但依那西普和甲氨蝶呤的联合应用增加了对活动期银屑病的治疗效果。《性爱学报》2008；88：495-501。资金来源：没有。
specific biologics: current knowledge and future prospects. Ther Drug Monit 2013; 35:588–94. 3 Carrascosa JM, van Doorn MB, Lahfa M et al. Clinical relevance of immunogenicity of biologics in psoriasis: implications for treatment strategies. J Eur Acad Dermatol Venereol 2014; 28:1424–30. 4 Jani M, Barton A, Warren RB et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) 2014; 53:213–22. 5 Pathirana D, Ormerod AD, Saiag P et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23(Suppl. 2):1–70. 6 Gottlieb AB, Langley RG, Strober BE et al. A randomized, doubleblind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol 2012; 167:649–57. 7 Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: doubleblind randomised controlled trial. Lancet 2004; 363:675–81. 8 Keystone EC, van der Heijde D, Kavanaugh A et al. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis. J Rheumatol 2013; 40:1487–97. 9 St Clair EW, van derHeijde DM, Smolen JS et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50:3432– 43. 10 Smolen JS, Landewe R, Breedveld FC et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73:492–509. 11 Gisondi P, Targher G, Zoppini G et al. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51:758–64. 12 van der Voort EA, Koehler EM, Dowlatshahi EA et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: results from a population-based study. J Am Acad Dermatol 2014; 70:517–24. 13 Lopez-Ferrer A, Vilarrasa E, Gich IJ et al. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre. Br J Dermatol 2013; 169:1141–7. 14 Antoniou C, Dessinioti C, Vergou T et al. Sequential treatment with biologics: switching from efalizumab to etanercept in 35 patients with high-need psoriasis. J Eur Acad Dermatol Venereol 2010; 24:1413–20. 15 Philipp S, Wilsmann-Theis D, Weyergraf A et al. Combination of adalimumab with traditional systemic antipsoriatic drugs – a report of 39 cases. J Dtsch Dermatol Ges 2012; 10:821–37. 16 van den Reek JM, van L€ umig PP, Kievit W et al. Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice. J Dermatolog Treat 2013; 24:361–8. 17 Dalaker M, Bonesrønning JH. Long-term maintenance treatment of moderate-to-severe plaque psoriasis with infliximab in combination with methotrexate or azathioprine in a retrospective cohort. J Eur Acad Dermatol Venereol 2009; 23:277–82. 18 Driessen RJ, van de Kerkhof PC, de Jong EM. Etanercept combined with methotrexate for high-need psoriasis. Br J Dermatol 2008; 159:460–3. 19 Zachariae C, Mørk NJ, Reunala T et al. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol 2008; 88:495–501. Funding sources: none.
影响因子：
45.3
作者：
Oberholzer, Patrick A.;Kee, Damien;Garraway, Levi A.
通讯作者：
Garraway, Levi A.